There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report) and Nutriband (NTRB – Research Report) with bullish sentiments.
BridgeBio Pharma (BBIO)
SVB Securities analyst Mani Foroohar maintained a Buy rating on BridgeBio Pharma today and set a price target of $30.00. The company’s shares closed last Tuesday at $10.28, close to its 52-week low of $4.98.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $21.75 average price target, an 81.9% upside from current levels. In a report released today, Mizuho Securities also assigned a Buy rating to the stock with a $25.00 price target.
See today’s best-performing stocks on TipRanks >>
Nutriband (NTRB)
In a report released today, Eric Beder from Small Cap Consumer Research maintained a Buy rating on Nutriband, with a price target of $21.00. The company’s shares closed last Tuesday at $6.30.
According to TipRanks.com, Beder is ranked #3239 out of 7953 analysts.
Nutriband has an analyst consensus of Moderate Buy.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BBIO:
- TransUnion (TRU) Receives a Hold from Needham
- Analysts’ Top Healthcare Picks: Galectin Therapeutics (GALT), Clearside Biomedical (CLSD)
- Analysts’ Opinions Are Mixed on These Materials Stocks: Yamana Gold (AUY) and Anglo American (OtherAAUKF)
- Cleveland-Cliffs Stock: This Steelmaker’s a Steal at These Prices
- Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and IVERIC bio (ISEE)
